New Treatment Option for Severe Allergic Reactions
The FDA has recently approved dupilumab (Dupixent) for children as young as 6 months old with moderate-to-severe chronic spontaneous urticaria (CSU). This marks a significant advancement in pediatric allergy treatment.
What is Dupilumab?
Dupilumab is a monoclonal antibody that targets IL-4 receptor alpha, reducing allergic inflammation in the body. It’s administered via injection every two weeks.
Clinical Trial Results:
- Reduced hive severity by 75% in clinical trials
- Well-tolerated in children 6 months and older
- Improved quality of life for patients and families
Eligibility:
Children with chronic urticaria that doesn’t respond to antihistamines may be candidates for dupilumab therapy. Consult with an allergist to determine if this treatment is appropriate.